alisertib + rituximab

Alisertib + rituximab is an investigational combination therapy for relapsed or refractory aggressive B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). **Alisertib** is a selective small molecule inhibitor of Aurora A kinase, a serine/threonine kinase involved in regulating mitosis, which plays an oncogenic role when overexpressed. **Rituximab** is a monoclonal antibody targeting the CD20 antigen on B cells, mediating cytotoxicity through immune effector mechanisms. This combination exploits potential synergy, with alisertib inducing mitotic arrest and apoptosis and rituximab facilitating B cell depletion. Clinical studies have shown activity and tolerability for the combination in relapsed/refractory aggressive B-cell lymphomas[1][2][4].